rare disease

Transthyretin amyloid cardiomyopathy: Alexion granted an exclusive worldwide licence to develop, manufacture and commercialise NI006 as part of an agreement with Neurimmune AG

Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal…

2 years ago

AL Amyloidosis: Alexion, AstraZeneca Rare Disease, takes over Caelum Biosciences, Inc.

(PRESS RELEASE) CAMBRIDGE, 29-Sep-2021 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced its…

3 years ago

Shire to present new data on recombinant human parathyroid hormone and on the management of chronic hypoparathyroidism at the Endocrine Society’s 100th Annual Meeting and Exposition

Clinical and real-world insights on recombinant human parathyroid hormone (1-84) (rhPTH[1-84]) and the management of chronic hypoparathyroidism to be presented…

6 years ago

200 healthcare decision-makers gather to address the looming challenges of cost, access and sustainability in the coming wave of high-value medicines

LONDON, 01-Dec-2017 — /EuropaWire/ — On December 5-6, 2017, 200 high-level experts from government, academia, biopharmaceutical developers and patient organisations…

6 years ago

EURORDIS to represent people living with a rare disease across Europe in new EU-funded INNOVCare project

BRUSSELS, 24-11-2015 — /EuropaWire/ — EURORDIS will be the voice of people living with a rare disease across Europe in…

8 years ago